Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Chardan Capital Downgrades Vascular Biogenics to Neutral

Chardan Capital Downgrades Vascular Biogenics to Neutral

Chardan Capital analyst Matthew Barcus downgrades Vascular Biogenics (NASDAQ:VBLT) from Buy to Neutral.

byBenzinga Newsdesk

July 21, 2022

1 minute read

Chardan Capital analyst Matthew Barcus downgrades Vascular Biogenics (NASDAQ:VBLT) from Buy to Neutral.

Analyst Ratings

Where Frontier Communications Stands With Analysts

By Benzinga Insights

June 27, 11:00 AM

Within the last quarter, Frontier Communications (NASDAQ:FYBR) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…

FYBR

What’s Going On With Donald Trump Related Digital World Acquisition Stock Today

By Anusuya Lahiri

May 9, 1:40 PM

Digital World Acquisition Corp (NASDAQ: DWAC) shares are up Tuesday for no company-specific news. The Donald Trump-backed SPAC has been through a lot since Elon Musk reinstated the former U.S. President's account on Twitter.

DWAC